Did you know that an estimated 7 million (11.4%) of the children in the United States between the ages of 3 – 17 have ever been diagnosed with ADHD?
Attention-Deficit/Hyperactivity Disorder (ADHD) is a condition that affects both children and adults, impacting attention, impulsivity, and/or hyperactivity. Individuals with ADHD often struggle with remembering things, staying still, paying attention, or controlling their impulses. Symptoms often begin in childhood and can affect daily life. Common symptoms include:
🧠Lack of focus
🧠Fatigue
🧠Disorganization
🧠Poor time management skills
🧠Impulsivity
🧠Forgetfulness
🧠Lack of motivation
🧠Restlessness and anxiety
ADHD is more common in males than in females. Those with ADHD may also experience other conditions, such as anxiety disorders, learning disabilities, depression, behavioral disorders, or substance use disorders. While there is no cure for ADHD, various treatments can help to reduce symptoms and improve functioning. Treatment options may include behavior therapy and/or medication, with recommendations varying based on age. Behavior therapy can involve behavior management, skills training, and psychological counseling. Medication options may include non-stimulant or stimulant medications, such as:
💊Atomoxetine (Strattera)
💊Clonidine (Onyda XR)
💊Dextroamphetamine/amphetamine (Adderall)
💊Dexmethylphenidate (Focalin)
💊Guanfacine (Intuniv)
💊Lisdexamfetamine (Vyvanse)
💊Methylphenidate (Ritalin/Concerta)
💊Viloxazine (Qelbree)
If you or someone you know is experiencing these symptoms, please contact a doctor or primary care provider to schedule an evaluation and discuss treatment options.
References
- Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder (ADHD). https://www.cdc.gov/adhd/data/index.html
- National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
Discover more from CCOPHARMA
Subscribe to get the latest posts sent to your email.
0 Comments